Delivery Order SPE2DB22D1017-SPE2DB25FYPNJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $35,657.00 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract specifies a place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $37,758.82 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $24,779.66 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded contract—not utilizing any set-aside designation—will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $20,876.59 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting the federal government's pharmaceutical supply chain. The contract will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $9,106.78 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $3,397.26 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 19, 2025. This firm fixed price, competitively awarded delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. The contract represents a continuation of the contractor's ongoing support to federal healthcare systems through pharmaceutical...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPNJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,385.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 29, 2025, with an ultimate completion date of September 2, 2025. This non-competitive, firm fixed-price delivery order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, fulfilling medical procurement needs for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026. The parent IDC enables the company to supply a wide range of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities to support military healthcare programs globally, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The current delivery order for Dupixent, a biologic medication used for treating eczema and other inflammatory conditions, demonstrates the vendor's ongoing capacity to fulfill specialized pharmaceutical requirements within the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.4k | 8/29/25 |